{
  "abstract": "BACKGROUND: The clinical consequences of discontinuing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have not been elucidated. METHODS AND RESULTS: We analyzed 208 patients with coronary artery disease treated with PCSK9 inhibitors. During a median follow-up of 1,096 days, 94 patients discontinued treatment and they had a higher incidence of major adverse cardiovascular events (MACE) than those who continued. Event curves diverged approximately 3 years after discontinuation. Multivariable Cox analysis showed that discontinuation was associated with a higher incidence of MACE. CONCLUSIONS: Discontinuation of PCSK9 inhibitors was associated with worse cardiovascular outcomes.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "name": "Hideo Tsubata"
    },
    {
      "name": "Naohiko Nakanishi"
    },
    {
      "name": "Noriyuki Wakana"
    },
    {
      "name": "Arito Yukawa"
    },
    {
      "name": "Norimasa Taniguchi"
    },
    {
      "name": "Hirokazu Yokoi"
    },
    {
      "name": "Kiyonari Matsuo"
    },
    {
      "name": "Natsuya Keira"
    },
    {
      "name": "Takashi Okada"
    },
    {
      "name": "Keizo Furukawa"
    },
    {
      "name": "Masahiro Koide"
    },
    {
      "name": "Satoaki Matoba"
    },
    {
      "name": "on behalf of the Kyoto PCSK9 Registry"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0wjb3sh68783t.bib",
  "cited_by": 1,
  "doi": "10.1253/circj.cj-26-0460",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0460/_article",
  "id": "0wjb3sh68783t",
  "issns": [
    "1347-4820",
    "1346-9843"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0460/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/cardiovascular"
    ],
    [
      "openalex",
      "2746|Lipoproteins and Cardiovascular Health"
    ]
  ],
  "openalex": "W7167928814",
  "pdf_url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0460/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-07-11",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/0wjb3sh68783t.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:24Z",
      "native_id": "10.1253/circj.cj-26-0460",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0460/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2746|Lipoproteins and Cardiovascular Health",
      "subfield": "surgery"
    }
  ],
  "title": "Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―",
  "title_text": "Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:24Z",
  "url": "https://research.draconitic.com/paper/0wjb3sh68783t",
  "venue": "Circulation Journal",
  "versions": []
}